PRNewsWire
19 Mar 2026, 13:00 UTC · 32w ago
Impact · against what's priced in
The news is largely non-material for the listed companies as it consists of legal solicitations following previously disclosed events. For Snowflake, the lawsuit stems from the already-realized 18% price drop and the withdrawal of a revenue target, providing no new fundamental catalyst.
No priced-in read yet
What the story claims
2 claims · scored −1 bearish … +1 bullish
Snowflake withdrew its $10 billion product revenue target and disclosed consumption headwinds, resulting in an 18.14% share price decline.
So whatThe withdrawal of a major long-term revenue target and admission of fundamental business headwinds directly impair valuation and growth expectations.
More negative than 99% of claims this week
A legal firm is soliciting lead plaintiffs for a securities class action alleging Snowflake misled investors about the impact of Iceberg Tables and efficiency gains on consumption revenue.
Continue reading
5 related stories
The firm is investigating potential claims after shares fell 22% following a Q1 FY 2026 miss and lowered full-year guidance.
Read from the article alone
No priced-in read yet
The article details a securities class action lawsuit following an 18.14% share price drop triggered by the withdrawal of a $10 billion product revenue target.
Read from the article alone
No priced-in read yet
The firm is soliciting investors after shares fell 24% due to a negative opinion from the European Medicines Agency's CHMP.
Read from the article alone
Scored by the NIS engine · methodology.
Top 3 movers · tap to explore
More negative than 79% of claims this week
Which stocks this story touches
More negative than 99% of ticker scores this week
Shares fell roughly 22% after missing Q1 FY 2026 expectations and cutting full-year guidance.
More negative than 99% of ticker scores this week
The company is facing a securities class action lawsuit following an 18% stock drop and the withdrawal of a major revenue target.
More negative than 99% of ticker scores this week
Shares fell approximately 24% following a negative opinion from the European Medicines Agency's CHMP.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Newsfile Corp
3h ago
+76.7%
Price is moving against the score
$306.08 vs $173.25 close before publication (Mar 18) · not market-adjusted
SNOW chart →+7.6%
Price is moving against the score
$10.28 vs $9.55 close before publication (Mar 18) · not market-adjusted
ZVRA chart →−24.3%
Price agrees with the score
$13.08 vs $17.28 close before publication (Mar 18) · not market-adjusted
ACI chart →
